

# Timothy D Warner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9090591/publications.pdf>

Version: 2024-02-01

256  
papers

16,958  
citations

22099

59  
h-index

16127

124  
g-index

268  
all docs

268  
docs citations

268  
times ranked

14549  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7563-7568.	3.3	1,436
2	Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9797-9800.	3.3	1,293
3	Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10480-10484.	3.3	897
4	Isoforms of nitric oxide synthase Characterization and purification from different cell types. Biochemical Pharmacology, 1991, 42, 1849-1857.	2.0	813
5	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB Journal, 2004, 18, 790-804.	0.2	532
6	Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science, 1992, 255, 721-723.	6.0	419
7	Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circulation Research, 2013, 112, 595-600.	2.0	366
8	Coinduction of nitric oxide synthase and cyclooxygenase: interactions between nitric oxide and prostanoids. British Journal of Pharmacology, 1995, 114, 1335-1342.	2.7	318
9	Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. Journal of Cardiovascular Pharmacology, 1989, 13, S85-88.	0.8	276
10	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. Journal of Immunology, 2009, 183, 2089-2096.	0.4	272
11	Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. European Journal of Pharmacology, 1989, 159, 325-326.	1.7	257
12	Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13371-13373.	3.3	252
13	Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2334-2338.	3.3	250
14	COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery, 2006, 5, 75-86.	21.5	235
15	Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. British Journal of Pharmacology, 1999, 128, 1121-1132.	2.7	234
16	Activation of PPAR $\gamma$ Induces Endothelial Cell Proliferation and Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 63-69.	1.1	220
17	Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Molecular Pharmacology, 1992, 41, 615-24.	1.0	209
18	Expression and activation of the farnesoid X receptor in the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3668-3673.	3.3	203

#	ARTICLE	IF	CITATIONS
19	Antiplatelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual antiplatelet therapy. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 619-633.	1.1	172
20	Association of MicroRNAs and YRNAs With Platelet Function. <i>Circulation Research</i> , 2016, 118, 420-432.	2.0	167
21	Use of the endothelin antagonists BQ123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. <i>British Journal of Pharmacology</i> , 1993, 110, 777-782.	2.7	165
22	Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> , 2001, 56, 30-35.	2.7	163
23	The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression. <i>Cancer Research</i> , 2006, 66, 10120-10126.	0.4	157
24	In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 552-561.	1.9	157
25	Endothelin-1 Release from Endothelial Cells in Culture Is Elevated Both Acutely and Chronically by Short Periods of Mechanical Stretch. <i>Biochemical and Biophysical Research Communications</i> , 1994, 200, 395-400.	1.0	147
26	Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2606-2611.	1.1	144
27	COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. <i>Lancet</i> , 2008, 371, 270-273.	6.3	143
28	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. <i>Journal of Clinical Investigation</i> , 2019, 129, 1845-1862.	3.9	136
29	Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. <i>British Journal of Pharmacology</i> , 1993, 109, 265-270.	2.7	126
30	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1993, 108, 776-779.	2.7	123
31	Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 706-711.	1.1	113
32	Cellular mechanisms of acetaminophen: role of cyclooxygenase. <i>FASEB Journal</i> , 2005, 19, 1-15.	0.2	110
33	Effects of Cyclic GMP on Smooth Muscle Relaxation. <i>Advances in Pharmacology</i> , 1994, 26, 171-194.	1.2	106
34	Origins of Prostaglandin E2: Involvements of Cyclooxygenase (COX)-1 and COX-2 in Human and Rat Systems. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 1001-1006.	1.3	105
35	Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17597-17602.	3.3	105
36	Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR $\gamma$ . <i>FASEB Journal</i> , 2006, 20, 326-328.	0.2	101

#	ARTICLE	IF	CITATIONS
37	Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. <i>Molecular Pharmacology</i> , 1999, 55, 902-9.	1.0	93
38	Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. <i>British Journal of Pharmacology</i> , 1997, 121, 125-133.	2.7	87
39	Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 2691-2695.	3.3	82
40	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor $\hat{1}^2$ Receptors in Prostacyclin Sensing by Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 34, 242-246.	1.4	79
41	Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. <i>British Journal of Pharmacology</i> , 1999, 126, 1824-1830.	2.7	77
42	Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 104-110.	1.4	77
43	Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. <i>British Journal of Pharmacology</i> , 1990, 99, 427-433.	2.7	76
44	Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. <i>Blood</i> , 2007, 109, 3741-3744.	0.6	75
45	A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. <i>British Journal of Pharmacology</i> , 1999, 127, 1589-1596.	2.7	74
46	The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 919-925.	1.0	73
47	Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 613-615.	1.9	73
48	Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine. <i>Circulation</i> , 2015, 131, 633-642.	1.6	73
49	Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17444-17449.	3.3	73
50	Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. <i>FASEB Journal</i> , 2006, 20, 2468-2475.	0.2	71
51	Role of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 384-391.	1.1	71
52	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. <i>PLoS ONE</i> , 2011, 6, e26591.	1.1	71
53	Selective COX-2 inhibitors and human inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1115-1117.	1.9	67
54	Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2103-2105.	1.9	66

#	ARTICLE	IF	CITATIONS
55	PPAR $\beta$ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor- $\beta$ antagonist. <i>FASEB Journal</i> , 2003, 17, 1-15.	0.2	65
56	RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1999, 26, 247-252.	0.9	62
57	Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2- $\beta$ . <i>Gut</i> , 2014, 63, 96-104.	6.1	62
58	Activation of peroxisome proliferator-activated receptor- $\beta$ by troglitazone (TGZ) inhibits human lung cell growth. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 760-774.	1.2	61
59	Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1933-1943.	1.9	61
60	Evidence from receptor antagonists of an important role for ET <sub>B</sub> receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. <i>British Journal of Pharmacology</i> , 1994, 111, 515-520.	2.7	60
61	Bisphenol A diglycidyl ether (BADGE) is a PPAR $\beta$ agonist in an ECV304 cell line. <i>British Journal of Pharmacology</i> , 2000, 131, 651-654.	2.7	60
62	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. <i>Blood</i> , 2014, 123, e11-e22.	0.6	60
63	Reversal of established responses to endothelin-1 <i>in vivo</i> and <i>in vitro</i> by the endothelin receptor antagonists, BQ-123 and PD 145065. <i>British Journal of Pharmacology</i> , 1994, 112, 207-213.	2.7	59
64	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 949-956.	1.1	59
65	Intimal Smooth Muscle Cells as a Target for Peroxisome Proliferator-Activated Receptor- $\beta$ Ligand Therapy. <i>Circulation Research</i> , 2002, 91, 210-217.	2.0	58
66	Role for Nuclear Factor- $\kappa$ B and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells. <i>Molecular Pharmacology</i> , 2003, 64, 923-931.	1.0	58
67	The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPAR $\beta$ In Vitro and In Vivo. <i>PLoS ONE</i> , 2009, 4, e7421.	1.1	58
68	Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. <i>European Journal of Pharmacology</i> , 1991, 204, 329-334.	1.7	56
69	Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4637-4642.	3.3	56
70	COX-2 Protects against Atherosclerosis Independently of Local Vascular Prostacyclin: Identification of COX-2 Associated Pathways Implicate Rgl1 and Lymphocyte Networks. <i>PLoS ONE</i> , 2014, 9, e98165.	1.1	56
71	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20483-20488.	3.3	55
72	Clopidogrel withdrawal: Is there a "rebound" phenomenon?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 211-220.	1.8	55

#	ARTICLE	IF	CITATIONS
73	LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 Expression. <i>PLoS ONE</i> , 2013, 8, e69524.	1.1	54
74	Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. <i>Biochemical Pharmacology</i> , 1990, 39, R21-R22.	2.0	53
75	COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. <i>FASEB Journal</i> , 2008, 22, 4005-4010.	0.2	53
76	The contribution of tumour necrosis factor- $\alpha$ and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. <i>British Journal of Pharmacology</i> , 1995, 116, 3309-3315.	2.7	52
77	Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo : investigations using the selective inhibitors, 1400W and celecoxib. <i>British Journal of Pharmacology</i> , 1998, 125, 335-340.	2.7	52
78	COX-2 in Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 956-958.	1.1	52
79	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15812-15817.	3.3	52
80	Blockade of the purinergic P2Y <sub>12</sub> receptor greatly increases the platelet inhibitory actions of nitric oxide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15782-15787.	3.3	52
81	Comparative Studies with the Endothelin Receptor Antagonists BQ-123 and PD 142893 Indicate At Least Three Endothelin Receptors. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, S117-S120.	0.8	50
82	Characterization of ET <sub>B</sub> receptors mediating contractions induced by endothelin-1 or IRL 1620 in guinea pig isolated airways: effects of BQ-123, FR139317 or PD 145065. <i>British Journal of Pharmacology</i> , 1994, 111, 1009-1016.	2.7	49
83	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). <i>British Journal of Pharmacology</i> , 2019, 176, 988-999.	2.7	49
84	Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I <sub>2</sub> : Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 642-647.	1.3	48
85	Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. <i>Cardiovascular Research</i> , 2012, 93, 674-681.	1.8	48
86	A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1991, 261, H598-H603.	1.5	47
87	Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach. <i>British Journal of Pharmacology</i> , 1994, 113, 1197-1202.	2.7	47
88	Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. <i>Platelets</i> , 2011, 22, 485-494.	1.1	47
89	4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A <sub>2</sub> and its receptor. <i>Oncogene</i> , 2011, 30, 106-116.	2.6	47
90	Nomenclature for COX-2 Inhibitors. <i>Lancet</i> , The, 2000, 356, 1373-1374.	6.3	46

#	ARTICLE	IF	CITATIONS
91	Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. <i>British Journal of Pharmacology</i> , 2002, 137, 1031-1038.	2.7	46
92	Endothelial cells have a particulate enzyme system responsible for EDRF formation: Measurement by vascular relaxation. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 1417-1423.	1.0	45
93	Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. <i>Clinical and Experimental Immunology</i> , 2002, 127, 263-269.	1.1	45
94	Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. <i>British Journal of Pharmacology</i> , 1993, 110, 687-692.	2.7	44
95	Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. <i>British Journal of Pharmacology</i> , 1995, 114, 1673-1679.	2.7	44
96	Synergy between cyclooxygenase-2 induction and arachidonic acid supply <i>in vivo</i> : consequences for nonsteroidal antiinflammatory drug efficacy. <i>FASEB Journal</i> , 1999, 13, 245-251.	0.2	44
97	Aspirin inhibits the production of proangiogenic 15 <i>S</i> -HETE by platelet cyclooxygenase-1. <i>FASEB Journal</i> , 2016, 30, 4256-4266.	0.2	44
98	Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. <i>Thrombosis and Haemostasis</i> , 2009, 102, 772-778.	1.8	43
99	PPAR $\beta$ Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKC $\zeta$ . Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1871-1873.	1.1	43
100	Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 249-256.	1.0	43
101	Endothelin receptor antagonists: Actions and rationale for their development. <i>Biochemical Pharmacology</i> , 1994, 48, 625-635.	2.0	42
102	Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. <i>FASEB Journal</i> , 2006, 20, 542-544.	0.2	41
103	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. <i>Heart</i> , 2010, 96, 1693-1694.	1.2	41
104	Regulation of Cyclo-oxygenase Gene Expression in Rat Smooth Muscle Cells by Catalase. <i>Biochemical Pharmacology</i> , 1998, 55, 1621-1631.	2.0	39
105	Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages. <i>Molecular Pharmacology</i> , 1992, 41, 1163-8.	1.0	39
106	Interleukin-1 $\beta$ , but not interleukin-6, enhances renal and systemic endothelin production <i>in vivo</i> . <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F446-F453.	1.3	38
107	Cytokine and Lipopolysaccharide Stimulation of Endothelin-1 Release from Human Internal Mammary Artery and Saphenous Vein Smooth-Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S348-S350.	0.8	38
108	Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. <i>European Journal of Pharmacology</i> , 1993, 250, 447-453.	1.7	37



#	ARTICLE	IF	CITATIONS
109	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. <i>Vascular Pharmacology</i> , 2015, 71, 70-78.	1.0	37
110	Different patterns of release of endothelium-derived relaxing factor and prostacyclin. <i>British Journal of Pharmacology</i> , 1992, 105, 485-489.	2.7	36
111	Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse. <i>PLoS ONE</i> , 2011, 6, e20062.	1.1	36
112	Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea pig ileum. <i>British Journal of Pharmacology</i> , 1993, 110, 783-789.	2.7	35
113	Cyclooxygenases and the cardiovascular system. , 2021, 217, 107624.		35
114	Endothelin Receptor Antagonists. <i>Cardiovascular Drug Reviews</i> , 1994, 12, 105-122.	4.4	34
115	What turns on the endothelins?. <i>Inflammation Research</i> , 1996, 45, 51-53.	1.6	33
116	Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. <i>Heart</i> , 2011, 97, 1661-1667.	1.2	33
117	Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. <i>British Journal of Pharmacology</i> , 1995, 116, 2482-2486.	2.7	32
118	Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2050-2056.	1.9	32
119	Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor- $\kappa$ B activation. <i>Life Sciences</i> , 1999, 64, 1231-1242.	2.0	31
120	Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. <i>Platelets</i> , 2012, 23, 404-408.	1.1	31
121	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 49-62.	1.1	31
122	Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea pig. <i>British Journal of Pharmacology</i> , 1995, 115, 1319-1325.	2.7	30
123	The Prostacyclin-Mimetic Cicaprost Inhibits Endogenous Endothelin-1 Release From Human Pulmonary Artery Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S410-S413.	0.8	30
124	Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 517-530.	2.6	30
125	Inhibition of profibrotic microRNA-21 affects platelets and their releasate. <i>JCI Insight</i> , 2018, 3, .	2.3	30
126	Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. <i>European Journal of Pharmacology</i> , 2001, 426, 95-103.	1.7	29



#	ARTICLE	IF	CITATIONS
127	Loss of GPVI and GPIb $\beta$ contributes to trauma-induced platelet dysfunction in severely injured patients. <i>Blood Advances</i> , 2020, 4, 2623-2630.	2.5	29
128	Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. <i>Blood</i> , 2015, 126, e11-e18.	0.6	28
129	Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A $_{2}$ Proves Renal Origins of Urinary PGI-M and TX-M. <i>Circulation Research</i> , 2018, 122, 555-559.	2.0	28
130	Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. <i>British Journal of Pharmacology</i> , 1992, 106, 948-952.	2.7	27
131	Characterization of endothelin (ET) receptors in the isolated gall bladder of the guinea pig: evidence for an additional ET receptor subtype. <i>British Journal of Pharmacology</i> , 1994, 112, 1244-1250.	2.7	27
132	Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension. <i>Molecular Pharmacology</i> , 2002, 62, 1147-1153.	1.0	27
133	P2Y $_{12}$ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 621-633.	1.1	27
134	96-well plate-based aggregometry. <i>Platelets</i> , 2018, 29, 650-655.	1.1	27
135	Endothelin increases cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1991, 259, 1102-8.	1.3	27
136	Inherited human group IVA cytosolic phospholipase A $_{2}$ deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. <i>FASEB Journal</i> , 2015, 29, 4568-4578.	0.2	26
137	Endothelin versatility. <i>Nature</i> , 1995, 375, 539-540.	13.7	25
138	Gasotransmitters and platelets. , 2011, 132, 196-203.		25
139	Alkaline buffers release EDRF from bovine cultured aortic endothelial cells. <i>British Journal of Pharmacology</i> , 1991, 103, 1295-1302.	2.7	24
140	Human Big Endothelin Releases Prostacyclin in vivo and in vitro Through a Phosphoramidon-Sensitive Conversion to Endothelin-1. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, S251-255.	0.8	24
141	Double-edged role of endogenous nitric oxide. <i>Lancet, The</i> , 1992, 339, 986.	6.3	24
142	Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. <i>Free Radical Research</i> , 2000, 32, 223-234.	1.5	24
143	Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. <i>Life Sciences</i> , 2002, 71, 1893-1904.	2.0	24
144	Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1897-1905.	1.9	23

#	ARTICLE	IF	CITATIONS
145	Proteome and functional decline as platelets age in the circulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3095-3112.	1.9	23
146	Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 288, 1101-6.	1.3	23
147	Increased thromboxane B2 levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. <i>Cancer Letters</i> , 2006, 234, 193-198.	3.2	22
148	Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. <i>British Journal of Pharmacology</i> , 2010, 160, 1997-2007.	2.7	22
149	Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox. <i>Circulation Research</i> , 2019, 125, 847-854.	2.0	22
150	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S407-S409.	0.8	20
151	MODULATION BY COLONY STIMULATING FACTORS OF HUMAN EPITHELIAL COLON CANCER CELL APOPTOSIS. <i>Cytokine</i> , 2002, 20, 163-167.	1.4	20
152	Aspirin-triggered 15-epi-lipoxin A <sub>4</sub> predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. <i>FASEB Journal</i> , 2013, 27, 3938-3946.	0.2	20
153	Vasoconstriction in the Rat Kidney Induced by Endothelin-1 Is Blocked by PD 145065. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, S103-S106.	0.8	19
154	Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. <i>European Journal of Pharmacology</i> , 1997, 324, 219-222.	1.7	19
155	Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels. <i>Acta Physiologica</i> , 2018, 223, e13028.	1.8	18
156	The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. <i>British Journal of Pharmacology</i> , 1994, 112, 289-291.	2.7	17
157	Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9108-9110.	3.3	17
158	Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. <i>Experimental Cell Research</i> , 2009, 315, 2974-2981.	1.2	17
159	Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1482-1493.	1.1	17
160	Effects of nitric oxide-modulating amino acids on coronary vessels: relevance to sepsis. <i>European Journal of Pharmacology</i> , 2000, 389, 209-215.	1.7	16
161	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2122-2133.	1.1	16
162	Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. <i>Platelets</i> , 2018, 29, 686-689.	1.1	16

#	ARTICLE	IF	CITATIONS
163	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
164	Human brain contains a metalloprotease that converts big endothelin to endothelin and is inhibited by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 505-506.	2.7	15
165	Human Platelets Utilize Cyclooxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. Journal of Biological Chemistry, 2016, 291, 13448-13464.	1.6	15
166	Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. American Journal of Physiology - Heart and Circulatory Physiology, 1992, 262, H1600-H1605.	1.5	14
167	Synthesis and biological activity of the novel nitric oxide synthase inhibitor N <sup>1</sup> -hydroxy-N <sup>1</sup> -methyl-L-arginine. Journal of the Chemical Society Perkin Transactions 1, 1994, , 769-771.	0.9	14
168	Endothelin-1 Mediates Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines. Journal of Cardiovascular Pharmacology, 1995, 26, S419-421.	0.8	14
169	Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. British Journal of Pharmacology, 2001, 134, 1237-1244.	2.7	13
170	High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thrombosis Research, 2013, 131, 313-319.	0.8	13
171	Characterization of endothelin-converting enzyme from endothelial cells and rat brain: detection of the formation of biologically active endothelin-1 by rapid bioassay. Molecular Pharmacology, 1992, 41, 399-403.	1.0	13
172	Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. Journal of Pharmacology and Experimental Therapeutics, 1995, 275, 120-6.	1.3	13
173	Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis, 2020, 120, 253-261.	1.8	12
174	Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. International Angiology, 1996, 15, 93-9.	0.4	12
175	Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 894-900.	1.3	12
176	Characterization of Serine Protease-Derived Metabolites of Big Endothelin in the Cytosolic Fraction from Human Polymorphonuclear Leukocytes. Journal of Cardiovascular Pharmacology, 1992, 20, S22-S24.	0.8	11
177	Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. European Journal of Pharmacology, 1994, 252, 341-345.	1.7	11
178	Inhibition of ETB Receptors Limits the Efficacy of Nonselective Endothelin Antagonists In Vivo. Journal of Cardiovascular Pharmacology, 1995, 26, S177-179.	0.8	11
179	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers. American Journal of Cardiovascular Drugs, 2012, 12, 217-224.	1.0	11
180	Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. British Journal of Pharmacology, 1995, 114, 867-871.	2.7	10

#	ARTICLE	IF	CITATIONS
181	Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. <i>British Journal of Pharmacology</i> , 1996, 118, 21-26.	2.7	10
182	Cyclo-oxygenase-2 inhibitors and cardiovascular events. <i>Lancet, The</i> , 2002, 360, 1700-1701.	6.3	10
183	Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. <i>British Journal of Cancer</i> , 2002, 86, 1316-1321.	2.9	10
184	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. <i>Platelets</i> , 2015, 26, 689-692.	1.1	10
185	Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 762-766.	1.0	10
186	Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. <i>FASEB Journal</i> , 2020, 34, 10027-10040.	0.2	10
187	Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. <i>Biochemical and Biophysical Research Communications</i> , 1990, 172, 745-750.	1.0	9
188	Nitric oxide synthase in ferret brain: localization and characterization. <i>British Journal of Pharmacology</i> , 1992, 107, 849-852.	2.7	9
189	HIF, stretching to get control of VEGF. <i>Clinical Science</i> , 2003, 105, 393-394.	1.8	9
190	The Effect of NCX4016 [2-Acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl Ester] on the Consequences of Ischemia and Reperfusion in the Streptozotocin Diabetic Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 1107-1114.	1.3	9
191	Comparison of the survival of endothelium-derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat. <i>British Journal of Pharmacology</i> , 1989, 97, 777-782.	2.7	8
192	Detection by Bioassay and Specific Enzyme-Linked Immunosorbent Assay of Phosphoramidon-Inhibitable Endothelin-Converting Activity in Brain and Endothelium. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 20, S19-S21.	0.8	7
193	Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. <i>British Journal of Pharmacology</i> , 1995, 116, 2787-2789.	2.7	7
194	Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 357, 121-125.	1.4	7
195	Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet function. <i>Haematologica</i> , 2021, 106, 1423-1432.	1.7	7
196	Platelet inhibition by P2Y <sub>12</sub> antagonists is potentiated by adenosine signalling activators. <i>British Journal of Pharmacology</i> , 2021, 178, 4758-4771.	2.7	7
197	Endothelin-1 Stimulates Cyclic GMP Formation in Porcine Kidney Epithelial Cells via Activation of the L-Arginine-Dependent Soluble Guanylate Cyclase Pathway. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, S246-250.	0.8	6
198	ET touches down in Houston. <i>Nature</i> , 1993, 362, 497-498.	13.7	6

#	ARTICLE	IF	CITATIONS
199	NOS inhibitors in colitis: a suitable case for treatment?. <i>Gut</i> , 1998, 42, 152-153.	6.1	6
200	Cyclic AMP Regulates Cytokine Stimulation of Endothelin-1 Release in Human Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S404-S406.	0.8	6
201	NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. <i>European Journal of Pharmacology</i> , 2005, 508, 7-13.	1.7	6
202	IDENTIFICATION AND CHARACTERIZATION OF A DYSFUNCTIONAL CARDIAC MYOCYTE PHENOTYPE: ROLE OF BACTERIA, TOLL-LIKE RECEPTORS, AND ENDOTHELIN. <i>Shock</i> , 2007, 28, 434-440.	1.0	6
203	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. <i>Expert Review of Hematology</i> , 2016, 9, 223-225.	1.0	6
204	Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. <i>Platelets</i> , 2018, 29, 162-170.	1.1	6
205	5-HT <sub>3</sub> receptors do not mediate vagally-induced relaxation or contraction of the isolated stomach of the guinea-pig. <i>British Journal of Pharmacology</i> , 1994, 111, 346-350.	2.7	5
206	Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats. <i>European Journal of Pharmacology</i> , 1996, 316, 245-247.	1.7	5
207	Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. <i>Polish Journal of Pharmacology</i> , 1994, 46, 587-92.	0.3	5
208	Coronary vasoconstriction <i>in vitro</i> in the hearts of polyarthritic rats: effectiveness of <i>in vivo</i> treatment with the endothelin receptor antagonist SB 209670. <i>British Journal of Pharmacology</i> , 1995, 114, 1327-1328.	2.7	4
209	Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme. <i>British Journal of Pharmacology</i> , 1995, 114, 1383-1390.	2.7	4
210	Endothelin content, expression, and receptor type in normal and diseased human gallbladder. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1786-1792.	1.1	4
211	Discontinuation of Vioxx. <i>Lancet, The</i> , 2005, 365, 27-28.	6.3	4
212	Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1226-1228.	1.9	4
213	Smoking, atherothrombosis and clopidogrel. <i>Heart</i> , 2012, 98, 963-964.	1.2	4
214	Reply to Ricciotti et al.: Evidence for vascular COX isoforms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E184-E184.	3.3	4
215	Regulation of blood pressure by l-arginine-nitric oxide pathway within the superior colliculus of rats. <i>European Journal of Pharmacology</i> , 1997, 328, 65-67.	1.7	3
216	Activation of ETa receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. <i>Life Sciences</i> , 1997, 60, PL271-PL276.	2.0	3

#	ARTICLE	IF	CITATIONS
217	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S407-S409.	0.8	3
218	Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment" <i>Circulation Research</i> , 2018, 122, e84-e85.	2.0	3
219	Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age. <i>Circulation Research</i> , 2020, 127, 394-396.	2.0	3
220	Combination of cyclic nucleotide modulators with P2Y <sub>12</sub> receptor antagonists as antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1705-1713.	1.9	3
221	Response : Nitric Oxide and Arginine-Evoked Insulin Secretion. <i>Science</i> , 1992, 258, 1376-1378.	6.0	3
222	Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. <i>European Heart Journal</i> , 1993, 14 Suppl I, 42-7.	1.0	3
223	The Metabolism of Endothelin-1 and Big Endothelin-1 by the Isolated Perfused Kidney of the Rabbit. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, S65-S68.	0.8	2
224	A Single Competitive Reverse Transcriptase-Polymerase Chain Reaction Assay to Measure Inducible Nitric Oxide Synthase Gene Expression in Both Human and Rat. <i>Analytical Biochemistry</i> , 1997, 247, 455-458.	1.1	2
225	Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. <i>European Journal of Pharmacology</i> , 2002, 440, 71-77.	1.7	2
226	Expression of the P1A2 allele of glycoprotein IIIa and its impact on platelet function. <i>JRSM Cardiovascular Disease</i> , 2015, 4, 204800401561025.	0.4	2
227	Reply to Letter Regarding Article, "Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs" <i>Circulation</i> , 2015, 132, e213-4.	1.6	2
228	A novel genetic variant in <i>PTGS1</i> affects N-glycosylation of cyclooxygenase-1 causing a dominant negative effect on platelet function and bleeding diathesis. <i>American Journal of Hematology</i> , 2021, 96, E83-E88.	2.0	2
229	Shock news for the gut. <i>Gut</i> , 1998, 42, 606-606.	6.1	2
230	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. <i>Pathology</i> , 2022, 54, 746-754.	0.3	2
231	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. <i>Methods</i> , 1992, 1, 117-123.	0.5	1
232	N <sup>G</sup> -Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts. <i>Endothelium: Journal of Endothelial Cell Research</i> , 1995, 3, 121-129.	1.7	1
233	Short thromboelastography and the identification of high platelet reactivity while on and off therapy. <i>Heart</i> , 2012, 98, 679-680.	1.2	1
234	265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION:. <i>Heart</i> , 2013, 99, A139.3-A140.	1.2	1

#	ARTICLE	IF	CITATIONS
235	261 P2Y12 INHIBITION GREATLY POTENTIATES THE ANTI-PLATELET EFFECTS OF PROSTACYCLIN AND NITRIC OXIDE. Heart, 2013, 99, A137.2-A138.	1.2	1
236	Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. BMJ Open, 2015, 5, e005750-e005750.	0.8	1
237	Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Canadian Journal of Physiology and Pharmacology, 2017, 95, 954-960.	0.7	1
238	Irish society for gastroenterology. Irish Journal of Medical Science, 1994, 163, 37-47.	0.8	0
239	The molecular and biological basis for COX-2 selectivity. , 2004, , 41-65.		0
240	46 Urinary prostanoid metabolites in healthy volunteers taking prasugrel and aspirin. Heart, 2011, 97, e7-e7.	1.2	0
241	12 Relationship between proportions of P2Y12 inhibited platelets and aggregation in vitro. Heart, 2011, 97, e7-e7.	1.2	0
242	30 Investigation of the action of prostaglandin E2 on human platelets. Heart, 2011, 97, e7-e7.	1.2	0
243	22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel. Heart, 2011, 97, e7-e7.	1.2	0
244	207 PLATELET COX-1 SUPPORTS THE PRODUCTION OF BOTH PROSTANOIDS AND HETES. Heart, 2013, 99, A114.1-A114.	1.2	0
245	236 DURING ANTI-PLATELET THERAPY PLATELET TURNOVER MAY LEAD TO THE EMERGENCE OF A MINORITY OF UNINHIBITED PLATELETS SUFFICIENT TO INITIATE AND DRIVE PLATELET AGGREGATE FORMATION. Heart, 2013, 99, A126.2-A127.	1.2	0
246	In celebration of Professor Gus Bornâ€™s life, 29 July 1921 â€“ 16 April 2018. Platelets, 2018, 29, 743-743.	1.1	0
247	Cox2 reporter gene expression and prostacyclin mass spectrometry confirm vascular COXâ€™1 dominance for prostacyclin production. FASEB Journal, 2013, 27, 1b507.	0.2	0
248	<i>Response</i> : Nitric Oxide and Arginine-Evoked Insulin Secretion. Science, 1992, 258, 1376-1378.	6.0	0
249	Endothelins: Recent Progress. , 1995, , 313-318.		0
250	Cytokine Regulation of Endothelin Action. , 1998, , 89-100.		0
251	The Development of Specific Endothelin-Receptor Antagonists. , 1998, , 189-222.		0
252	Endothelin Receptors and Ligands. , 1999, , 21-48.		0



#	ARTICLE	IF	CITATIONS
253	Nitric oxide and endothelin-1 in circulatory shock involving cytokines. , 1999, , 151-171.		0
254	Understanding the cardiovascular effects of low dose aspirin by using a platelet COX-1-/- mouse model. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-2-57.	0.0	0
255	Platelet reactivity in an elderly and healthy population. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR25-2.	0.0	0
256	Endothelin-1 Mediates the Increase in Ex Vivo Coronary Vascular Resistance Induced by Hemorrhagic Shock in the Anesthetized Rat. Journal of Cardiovascular Pharmacology, 1995, 26, S422-424.	0.8	0